Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study

NCT07709624 is registered in ClinicalTrials.gov with TTY Biopharm as lead sponsor.

NCT NCT07709624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07709624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study
Lead sponsor
TTY Biopharm
Phase
Observational
Overall status
Active, not recruiting
Start date
December 1, 2025
Completion date
December 31, 2030
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dlbcl